PRELIMINARY REPORT OF THE USE ON ADULTS OF A RECOMBINANT YEAST-DERIVED HEPATITIS B VACCINE MANUFACTURED BY INSTITUTO BUTANTAN

Three 10 µg doses of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in a adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical trial was considered satisfactory in terms of immun...

Full description

Bibliographic Details

Published in:	Revista do Instituto de Medicina Tropical de São Paulo
Main Authors:	Angela Aparecida COSTA, Marta INENAMI, Edmundo JUAREZ, Pedro Dorlhiac LLACEN, Isaias RAW
Format:	Article
Language:	English
Published:	Universidade de São Paulo (USP) 1997-01-01
Subjects:	Recombinant hepatitis B vaccine Clinical trials Adults
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651997000100008